Abstract: A phased-array, conformal antenna and a method for forming same are disclosed. The method comprises forming a substantially planar layered antenna structure by fabricating a printed circuit board (PCB) on a substantially planar first substrate, adhering the PCB to a second substantially planar substrate, the second substantially planar substrate comprising an aerogel, adhering a plurality of antenna elements to the substantially planar second substrate to form the phased-array, adhering a protective layer to the one or more antenna elements, and shaping the substantially planar layered antenna structure to form a substantially curved layered antenna structure.

Abstract: The present disclosure generally pertains to methods of treating myocardial infarct involving administering a platelet anti-aggregate, a cysteine-aspartic protease inhibitor, and reperfusion therapy. In certain embodiments, the platelet anti-aggregate is at least one P2Y12 receptor antagonist or Glycoprotein IIb/IIIa inhibitor, the cysteine-aspartic protease inhibitor is selected from the group consisting of Caspase-1, 4, 5, 11 and 12 inhibitors, and reperfusion therapy is percutaneous coronary intervention. In certain embodiments, the at least one P2Y12 receptor antagonist is selected from the group consisting of cangrelor, ticagrelor, clopidogrel and prasugrel. The disclosed methods provide an improved cardioprotective effect against infarction when compared with the current standard of care.

Abstract: The present disclosure generally pertains to methods of treating myocardial infarct involving administering a platelet anti-aggregate, a cysteine-aspartic protease inhibitor, and reperfusion therapy. In certain embodiments, the platelet anti-aggregate is at least one P2Y12 receptor antagonist or Glycoprotein IIb/IIIa inhibitor, the cysteine-aspartic protease inhibitor is selected from the group consisting of Caspase-1, 4, 5, 11 and 12 inhibitors, and reperfusion therapy is percutaneous coronary intervention. In certain embodiments, the at least one P2Y12 receptor antagonist is selected from the group consisting of cangrelor, ticagrelor, clopidogrel and prasugrel. The disclosed methods provide an improved cardioprotective effect against infarction when compared with the current standard of care.

Abstract: A high efficiency secondary signal combiner may include a frequency division multiplexer that is configured to receive two or more signals and produce a combined signal. The combined signal may include the two or more signals, and each of the two or more signals may be in different Nyquist zones. The combiner may also include a wideband analog-to-digital converter (ADC) that is configured to frequency shift the combined signal by sub-sampling the two or more signals to produce a sub-sampled signal in a Nyquist zone that is different from the Nyquist zones of the two or more signals.

Abstract: The invention relates to substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines of formula (I) and their use in medicaments for the prophylaxis and/or treatment of reperfusion injury and damage.

Abstract: The invention is directed to pharmaceutical composition comprising a compound having adenosine A1/A2 agonistic activity, a sodium-hydrogen exchanger inhibitory compound and a pharmaceutically acceptable carrier. The invention is also directed to a method cardioprotection in a patient in need thereof comprising administering to said patient pharmaceutically effective amounts of a compound having adenosine A1/A2 agonistic activity and a sodium-hydrogen exchanger inhibitory compound. This invention is also directed to the use of pharmaceutically effective amounts of a compound having adenosine A1/A2 agonistic activity and a sodium-hydrogen exchanger inhibitory compound in the preparation of a medicament for providing cardioprotection to a patient in need thereof.

Abstract: This invention is directed to methods of providing cardioprotection in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, beginning at a time less than 10 minutes after the onset reperfusion, at reperfusion, and ten minutes or more before reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.

Abstract: Fostriecin and a compounds structurally related to fostriecin diminish myocardial infarction and delay the onset of cell injury in an ischemic heart. There is a strong correlation between myocardial protection and the inhibition of certain serine/threonine protein phosphatases. The present invention is drawn to a method for administering fostriecin as a pharmacological compound to reduce the size of a myocardial infarction. Further, administration of fostriecin is useful also as an adjunct therapy to treatment with thrombolytic agents or angioplasty to limit the size of infarction. The most advantageous feature of the method of the present invention is that administration of fostriecin diminishes infarct volume and cell injury even when added after ischemia conditions occurred.

Abstract: Methods for protecting tissues and organs including the heart central nervous system, and kidney from ischemic damage are described and claimed based upon the recognition that protection against infarction is mediated by A3 rather than A1 adenosine receptors, as was previously thought, and that the receptor mediating protection in other organs and tissues has not been defined. Methods for selectively stimulating A3 adenosine receptors are described and claimed, as such selection is shown to prevent or substantially reduce cell death resulting from ischemia with or without reperfusion in humans. According to this invention, the A3 adenosine receptor is selectively stimulated by administering a compound which is an A3 adenosine receptor-selective agonist. Prevention of tissue death is also achieved by administering a compound which is a non-selective adenosine receptor agonist together with compounds that act as antagonists to the A1 and A2 adenosine receptor.

Abstract: Methods for protecting tissues and organs including the heart central nervous system, and kidney from ischemic damage are described and claimed based upon the recognition that protection against infarction is mediated by A3 rather than A1 adenosine receptors, as was previously thought, and that the receptor mediating protection in other organs and tissues has not been defined. Methods for selectively stimulating A3 adenosine receptors are described and claimed, as such selection is shown to prevent or substantially reduce cell death resulting from ischemia with or without reperfusion in humans. According to this invention, the A3 adenosine receptor is selectively stimulated by administering a compound which is an A3 adenosine receptor-selective agonist. Prevention of tissue death is also achieved by administering a compound which is a non-selective adenosine receptor agonist together with compounds that act as antagonists to the A1 and A2 adenosine receptors.

Abstract: A vapor phase process for making methyl or ethyl nitrite from methanol or ethanol, respectively, by reacting a nitrogen oxide composition with methanol or ethanol.